Due to increasing regulatory requirements, the need for quality study and patient safety data is critical as we work together to bring our clients’ novel treatments to patients. PRA Health Sciences is diligently working to meet our clients’ data demands through the substantial growth of our Data Monitoring Committee (DMC) services over recent years. Staffed by a global team of experts, PRA’s dedicated DMC Unit ensures our clients’ projects meet the most stringent regulatory requirements.
Lighting the Night to Fight Cancer
Every year, more than 60,000 people are diagnosed with leukemia, and more than 382,000 live with the disease or are in remission.
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…
This week we bring you news of a gene therapy with the potential to change lives for children with Duchenne muscular dystrophy, having experienced…